Peripheral Signal Detection Was More Drug-Sensitive in a Cannabis–Alcohol Attention Study

A 1989 human study found larger cannabis and alcohol effects on peripheral than central signal detection. Cannabis users showed less peripheral impairment than non-users, but the authors left tolerance and compensation as alternative interpretations.

The comparison matched alcohol-use history

Cannabis users and non-users with matched alcohol use received cannabis, alcohol and combination conditions. Both drugs reduced central and peripheral detections, with larger effects for peripheral presentations. The location of a signal therefore mattered to the measured performance.

Less impairment did not mean no impairment

Users were less impaired on peripheral detection under cannabis and/or alcohol than non-users. That relative group difference does not establish normal functioning or protection across all task components. It also does not show that every regular user responds like the group average.

The mechanism was not uniquely identified

The authors proposed tolerance, cross-tolerance and/or compensation. Existing use history was not randomized, and better performance could reflect more than receptor adaptation. The task measured signal detection, not direct on-road behavior, crash risk or subjective awareness of impairment.

The study supports examining central and peripheral attention separately. It does not establish that experienced users can safely combine cannabis and alcohol or that feeling accustomed to the drugs predicts performance. Endpoint, use history and possible compensatory strategies should remain explicit.

Related: interpreting cannabis tolerance claims.

Research cited

Marks DF; MacAvoy MG. Divided attention performance in cannabis users and non-users following alcohol and cannabis separately and in combination. Psychopharmacology (1989). doi:10.1007/BF00445566. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

A review published in 2020 graded psychiatric evidence from studies of CBD and CBD-containing nabiximols. Its recommendation labels should not be quoted as though every underlying intervention was purified CBD or every study was randomized. The included designs ranged widely The review identified 23 relevant studies spanning case reports, case…

Spread the love

Read Article: A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

A 2021 ocular CBD review brought together in-vitro and in-vivo research, proposed molecular targets and possible therapeutic applications. This evidence maps a development pathway; it does not establish that CBD products are effective eye treatments. The experimental system belongs in the conclusion A cellular result can identify a target or…

Spread the love

Read Article: CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

A 2021 review evaluated CBD research on reinforcing, motivational and withdrawal-related drug effects. These outcomes can inform substance-use-disorder research, but an improvement in one cannot establish successful treatment across all of them. The source combined preclinical and clinical reports The review covered alcohol, opioids, cannabinoids, nicotine and psychostimulants. An animal…

Spread the love

Read Article: CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us